EMA Recommends Extension of Indications for Olaparib
New indication concerns maintenance treatment of metastatic adenocarcinoma of the pancreas with germline BRCA1/2-mutations
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
EMA Recommends Granting a Marketing Authorisation for Alpelisib
Alpelisib is intended for the treatment of advanced breast cancer with a PIK3CA mutation
FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
Evidence for efficacy is based on the results from the CHECKMATE-9LA study
FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC
FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic
ESMO Breast Cancer Virtual Meeting 2020: Results in Hormone Receptor-Positive and TNBC Subgroups from the Phase III BROCADE3 Trial
Improvement in progression-free survival reported.
FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
FDA also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic
FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic NSCLC with PD-L1 Tumour Expression ≥1%
FDA also approved the PD-L1 IHC 28-8 pharmDx as a companion diagnostic device
ESMO Breast Cancer Virtual Meeting 2020: Results of an Interim Analysis of the PHranceSCa Study
Patients with HER2-positive early breast cancer prefer a subcutaneous fixed-dose combination of pertuzumab and trastuzumab over intravenous treatment.
ESMO Breast Cancer Virtual Meeting 2020: Final Results of the LOTUS Study
Findings from the phase II study support further evaluation of ipatasertib plus paclitaxel in patients with advanced triple-negative breast cancer.
FDA Approves Olaparib for HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer
FDA also approved companion diagnostic devices for selection of patients
Cancer Care Among the Syrian Refugees
A population-based model study finds substantial financial burden for host countries and humanitarian agencies.
FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumour
Efficacy for evidence was evaluated in the INVICTUS study